An Open-Label Study of KW-2871 Administered With a Premedication Regimen in Patients With Advanced Stage IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Ecromeximab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Kirin Pharmaceutical Development
- 25 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 23 Jul 2007 status updated from nct
- 15 Oct 2005 New trial record.